Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12870257 | 1.00 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL1178044 | 1.00 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL1178045 | 1.00 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL27308951 | 0.93 | HSD17B10 (0.39) | NR1H2SMN1; SMN2CTSKHSD17B10MEN1 | |
| SCHEMBL27307619 | 0.93 | HSD17B10 (0.39) | NR1H2SMN1; SMN2CTSKHSD17B10MEN1 | |
| SCHEMBL29229184 | 0.93 | HSD17B10 (0.39) | NR1H2SMN1; SMN2CTSKHSD17B10MEN1 | |
| SCHEMBL30181410 | 0.88 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL16914071 | 0.83 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2CTSKHSD17B10 | |
| SCHEMBL23545833 | 0.82 | HSD17B10 (0.39) | NR1H2SMN1; SMN2CTSKHSD17B10MEN1 | |
| SCHEMBL29805015 | 0.82 | HSD17B10 (0.39) | NR1H2SMN1; SMN2CTSKHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486943-B2 | Tetrahydrocyclopenta[b]indole androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2297100-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2297100-A1 | TETRAHYDROCYCLOPENTAÝB¨INDOLE ANDROGEN RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | ELI LILLY AND COMPANY (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009140448-A1 | TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039855-A1 | Tetrahydrocyclopenta[b]indole Androgen Receptor Modulators | AR, ADRA1B, ADRB1 | NR1H2 111/4885USP2 4353/4885SMN1; SMN2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.